On this page
Chromosome 4
Site of the HTT gene - home of Huntington disease, the archetypal trinucleotide-repeat disorder.
Schematic of chromosome 4 showing the short (p) and long (q) arms. Arm ratio per GRCh38 - banding schematic.
Available at Jeen Health
Clinical tests that include this
Overview
Chromosome 4 is one of the mid-sized human autosomes, comprising roughly 6% of the total genome with approximately 190 million base pairs. It carries around 750 protein-coding genes, many of which perform essential roles in nervous-system signalling, skeletal growth, and organ development. Clinically, chromosome 4 is perhaps best recognised as the home of the HTT gene, where an unstable CAG trinucleotide repeat expansion causes Huntington disease, a progressive neurodegenerative disorder that became the first condition mapped by linkage analysis to a specific chromosomal region in 1983. The chromosome also carries FGFR3, pathogenic variants of which account for achondroplasia, the most frequent cause of disproportionate short stature worldwide.
Chromosome 4 is classified as submetacentric, meaning its centromere sits off-centre but not at the very end, dividing the chromosome into a shorter p arm and a longer q arm. This asymmetry is visible under the microscope during cell division, when the DNA condenses into its characteristic X shape. The chromosome's structure influences how genetic material is inherited and can predispose certain regions to rearrangements, particularly the terminal portion of the short arm, deletion of which produces Wolf-Hirschhorn syndrome.
Structure
Like all human chromosomes, chromosome 4 consists of a single, continuous double helix of DNA that extends from one telomere cap to the other. The centromere, located closer to one end, divides the molecule into the short p arm (approximately 50 million base pairs) and the long q arm (around 140 million base pairs). At metaphase, when the chromosome is most condensed for cell division, this submetacentric architecture is clearly visible. The centromere itself is built from highly repetitive alpha-satellite DNA sequences that recruit kinetochore proteins, ensuring the chromosome attaches correctly to spindle fibres and segregates evenly into daughter cells.
The DNA double helix does not exist as a naked thread inside the nucleus. Instead, it wraps around histone protein octamers to form nucleosomes, which themselves coil into progressively higher-order structures collectively termed chromatin. During most of the cell cycle, chromatin exists in a relatively open state that allows genes to be transcribed, but as the cell prepares to divide, the chromatin condenses thousands-fold into the compact, rod-like chromosome visible under a light microscope. This packaging protects the DNA during mitosis and meiosis whilst still permitting regulated access to the genetic information encoded within.
Video: What is a karyotype?
Notable regions
The cytogenetic band 4p16.3, at the very tip of the short arm, is arguably the most clinically significant region of chromosome 4. It contains the HTT gene, where expansion of a CAG trinucleotide repeat leads to production of an abnormally long polyglutamine tract in the huntingtin protein. This mutant protein misfolds and aggregates in neurons, triggering the progressive motor, cognitive, and psychiatric decline characteristic of Huntington disease. The same narrow region also harbours FGFR3, encoding fibroblast growth factor receptor 3, a key regulator of bone growth; a recurrent point mutation in FGFR3 accounts for the majority of achondroplasia cases. A separate cluster of developmental genes within 4p16.3 - distinct from HTT and FGFR3, and including WHSC1 (NSD2) and WHSC2 - defines the Wolf-Hirschhorn critical region; terminal deletions encompassing the Wolf-Hirschhorn critical region produce the syndrome. Importantly, HTT and FGFR3 haploinsufficiency are not responsible for the Wolf-Hirschhorn phenotype, even when a large terminal deletion happens to remove them alongside the critical region.
Wolf-Hirschhorn syndrome arises when a segment of 4p16.3 is deleted, typically de novo, removing this critical cluster of developmental genes. Affected individuals often present with a characteristic facial appearance (historically termed "Greek warrior helmet" profile due to a broad nasal bridge, high forehead, and prominent glabella), growth restriction, intellectual disability, and seizures. The size of the deletion varies, but loss of genes within the critical region appears necessary to produce the core features of the condition. Diagnosis is usually confirmed by chromosomal microarray or fluorescence in-situ hybridisation (FISH) following clinical suspicion based on physical examination and developmental concerns.
At the opposite end of the chromosome, cytogenetic band 4q35.2 harbours the D4Z4 macrosatellite repeat array. Contraction of this repeat array is associated with facioscapulohumeral muscular dystrophy, a progressive muscle-wasting disorder that preferentially affects the face, shoulder girdle, and upper arms. The mechanism is unusual: the contraction does not directly disrupt a protein-coding gene but instead alters chromatin structure, leading to inappropriate expression of DUX4 in skeletal muscle, which in turn triggers muscle-cell toxicity and inflammation.
Notable genes
Beyond HTT and FGFR3, chromosome 4 carries several other genes of considerable medical importance. PKD2, located on the long arm, is associated with autosomal dominant polycystic kidney disease type 2, characterised by the progressive growth of fluid-filled cysts in the kidneys, often leading to renal failure in adulthood. Although PKD2-related disease typically has a later onset and milder course than disease linked to PKD1 on a different chromosome, it remains a significant cause of end-stage kidney disease requiring dialysis or transplantation.
GABRB1, one of the genes in Jeen Health's curated launch set, encodes the beta-1 subunit of the GABA-A receptor, a ligand-gated chloride channel that mediates inhibitory neurotransmission in the brain. Variants in GABRB1 have been studied in the context of epilepsy and neurodevelopmental conditions. VEGFC encodes vascular endothelial growth factor C, a signalling protein involved in the formation of lymphatic vessels and, to a lesser extent, blood vessels. Research suggests that VEGFC plays a role in developmental processes and tissue repair, and dysregulation has been implicated in various pathological states.
Chromosomal disorders
Wolf-Hirschhorn syndrome is the hallmark structural abnormality of chromosome 4, arising from a terminal deletion of the short arm that removes the 4p16.3 critical region and often extends further proximally. Most cases result from a de novo deletion, though a minority are inherited from a parent carrying a balanced chromosomal rearrangement. Clinical features include prenatal and postnatal growth restriction, a distinctive craniofacial appearance, intellectual disability of variable severity, and seizures that can be difficult to control. Congenital heart defects, skeletal anomalies, and feeding difficulties are also frequently observed. The deletion is typically identifiable on a high-resolution karyotype or chromosomal microarray; smaller deletions may require targeted FISH or genomic sequencing. In the UK, ongoing care is typically coordinated through regional NHS clinical genetics services and multidisciplinary teams including paediatric neurology (for seizures), cardiology, orthopaedics, feeding specialists, and early-years developmental support.
Complete trisomy 4 or monosomy 4 is not compatible with survival to term, and non-mosaic cases have not been reported in liveborn individuals. Mosaic forms, where only a proportion of cells carry the extra or missing chromosome, have occasionally been reported but remain poorly characterised. The lack of viable complete trisomy or monosomy likely reflects the presence of dosage-sensitive genes whose imbalance disrupts fundamental developmental processes. In practice, clinically significant abnormalities of chromosome 4 are almost always structural, involving deletions, duplications, or rearrangements of specific segments rather than gain or loss of the entire chromosome.
Prenatal screening & diagnosis
Because whole-chromosome aneuploidy of chromosome 4 is not compatible with life, non-invasive prenatal testing (NIPT) panels do not routinely screen for trisomy 4 or monosomy 4. However, some extended NIPT platforms can detect large deletions or duplications, including terminal 4p deletions associated with Wolf-Hirschhorn syndrome, by analysing cell-free foetal DNA in maternal blood, though sensitivity varies and invasive testing is required for confirmation. In practice, Wolf-Hirschhorn is more often suspected following detailed ultrasound examination, which may reveal growth restriction, brain anomalies, or facial features suggestive of the syndrome. When imaging raises concern, invasive testing with amniocentesis or chorionic villus sampling is offered, and the sample is analysed by chromosomal microarray or karyotype to confirm or exclude a 4p deletion.
For families with a known history of a balanced chromosomal rearrangement involving chromosome 4, preconception or first-trimester counselling through NHS clinical genetics services may include discussion of preimplantation genetic testing for structural rearrangements (PGT-SR) or early prenatal diagnosis. Carrier parents have an increased risk of producing embryos with unbalanced translocations that may include partial deletions or duplications of chromosome 4. The NHS Fetal Anomaly Screening Programme does not include specific biomarkers for chromosome 4 abnormalities, but any significant structural anomaly detected on the mid-trimester scan can prompt referral to foetal medicine for further assessment, including genetic testing where appropriate.
Inheritance & recurrence
Most structural abnormalities of chromosome 4, including the deletions that cause Wolf-Hirschhorn syndrome, occur de novo, meaning they arise as new mutations during the formation of the egg or sperm or in early embryonic development. In these cases, the recurrence risk for future pregnancies is low, though this figure can be refined through parental karyotyping and, if appropriate, testing for germline mosaicism. A minority of cases are inherited from a parent who carries a balanced translocation or inversion involving chromosome 4. Such carriers are themselves healthy because no genetic material is lost or gained, but their offspring may inherit an unbalanced form of the rearrangement, resulting in a deletion or duplication. When a parent is found to carry a balanced rearrangement, the recurrence risk can be substantially higher, and detailed genetic counselling is essential.
For single-gene disorders on chromosome 4, the inheritance pattern depends on the condition. Huntington disease is autosomal dominant: each child of an affected parent has a 50% chance of inheriting the expanded HTT repeat. Achondroplasia, also autosomal dominant, is usually caused by a de novo FGFR3 mutation, but affected individuals can pass the variant to their children with the same 50% probability. Autosomal dominant polycystic kidney disease due to PKD2 similarly follows dominant inheritance. Families concerned about recurrence or wishing to explore reproductive options, including preimplantation genetic testing, are encouraged to seek referral to their local NHS clinical genetics service for individualised risk assessment and counselling.
Frequently asked questions
What is chromosome 4 best known for?
Chromosome 4 is best known as the location of the HTT gene, where expansion of a CAG trinucleotide repeat causes Huntington disease, a progressive neurodegenerative disorder. The chromosome also carries FGFR3, variants of which underlie achondroplasia, the most common form of short stature, and deletions of its short-arm tip cause Wolf-Hirschhorn syndrome.
How is Wolf-Hirschhorn syndrome diagnosed?
Wolf-Hirschhorn syndrome is typically diagnosed by chromosomal microarray or karyotype analysis performed on a blood sample, which identifies the terminal deletion of chromosome 4p16.3. In some cases, fluorescence in-situ hybridisation (FISH) may be used to confirm a suspected deletion. Referral for genetic testing usually follows clinical features such as distinctive facial appearance, growth delay, and developmental concerns.
Can chromosome 4 abnormalities be detected during pregnancy?
Large deletions of chromosome 4, such as those causing Wolf-Hirschhorn syndrome, may be detected by detailed ultrasound or, in some cases, extended non-invasive prenatal testing (NIPT). Confirmation requires invasive testing such as amniocentesis or chorionic villus sampling, followed by chromosomal microarray or karyotype analysis. Whole-chromosome trisomy or monosomy of chromosome 4 is extremely rare and generally not compatible with ongoing pregnancy.
If my child has a chromosome 4 deletion, will my next pregnancy be affected?
In most cases, deletions of chromosome 4 occur de novo (as new mutations) and the recurrence risk is low. However, it is important to have both parents' chromosomes checked by karyotype to rule out a balanced rearrangement, which would increase the recurrence risk. Your local NHS clinical genetics service can provide personalised counselling and discuss options such as prenatal diagnosis or preimplantation genetic testing for future pregnancies.
Are there treatments for conditions caused by chromosome 4 abnormalities?
There is currently no cure for chromosomal deletions such as Wolf-Hirschhorn syndrome, but supportive care can address many of the associated features, including physiotherapy, occupational therapy, antiepileptic medication for seizures, and input from specialists in cardiology, orthopaedics, and developmental paediatrics. For single-gene disorders like Huntington disease, management focuses on symptom control and supportive therapies, whilst research into disease-modifying treatments is ongoing. Your healthcare team will tailor a care plan to your individual needs.
Launch-set genes on chromosome 4
Genes on this chromosome that currently have dedicated pages in the library. This list grows as we publish more.